Strauss R, Gavras I, Vlahakos D, Gavras H
J Clin Pharmacol. 1986 Jan;26(1):39-43. doi: 10.1002/j.1552-4604.1986.tb02900.x.
Enalaprilat (MK-422), an intravenously administered angiotensin-converting enzyme inhibitor, which is the parent compound of the oral angiotensin-converting enzyme inhibitor enalapril (MK-421), was studied in 11 patients with asymptomatic accelerated hypertension. Each patient received an initial intravenous dose of 1 mg, followed at one-hour intervals by enalaprilat 10 mg, furosemide 40 mg, and enalaprilat 40 mg. Six of 11 patients responded with a drop in mean arterial pressure greater than 15 mm Hg to diastolic levels below 110 mm Hg; there were four partial responders and one nonresponder. Pretreatment renins were not predictive of blood pressure response. No patient had any adverse reaction to the drug; there were no significant changes in posttreatment laboratory values. We conclude that enalaprilat is an effective, well-tolerated agent for the treatment of uncomplicated accelerated hypertension and its use does not imperil nonresponding uncomplicated patients.
依那普利拉（MK - 422）是一种静脉注射用血管紧张素转换酶抑制剂，它是口服血管紧张素转换酶抑制剂依那普利（MK - 421）的母体化合物，在11例无症状性急进性高血压患者中进行了研究。每位患者初始静脉注射剂量为1毫克，随后每隔一小时依次给予依那普利拉10毫克、呋塞米40毫克和依那普利拉40毫克。11例患者中有6例平均动脉压下降超过15毫米汞柱，舒张压降至110毫米汞柱以下；有4例部分反应者和1例无反应者。治疗前的肾素水平不能预测血压反应。没有患者对该药物有任何不良反应；治疗后的实验室值没有显著变化。我们得出结论，依那普利拉是治疗单纯性急进性高血压的一种有效且耐受性良好的药物，其使用不会危及无反应的单纯性患者。
